πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Patent portfolio

Regeneron UK Patents

Full USPTO pharma patent portfolio for Regeneron UK β€” grant dates, expiration, and drug cross-links.

Patents
837
Expiring ≀24m
26

Quick answer

Regeneron UK has 837 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 26 expire within 24 months β€” use filters for patent-cliff planning.

Page 11 of 18

  1. US 10463748

    Human antibodies to S. aureus Hemolysin A toxin

    Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10457725

    Methods of treating skin cancer by administering a PD-1 inhibitor

    Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10442864

    Anti-Tie2 antibodies and uses thereof

    Expires Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10442856

    Methods of treating obesity with anti-ANGPTL8 antibodies

    Expires Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10435473

    Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

    Expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10428157

    Dosing regimens for use with PCSK9 inhibitors

    Expires Mon Sep 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10428135

    Fusion polypeptides capable of activating receptors

    Expires Mon Sep 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10426146

    Non-human animals having a humanized signal-regulatory protein gene

    Expires Mon Sep 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10426848

    Humanized FcΞ³R mice

    Expires Mon Sep 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10421804

    Anti-Zika virus antibodies and methods of use

    Expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10406222

    Human antibodies to Middle East Respiratory Syndromeβ€”coronavirus spike protein

    Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10406226

    Method of manufacturing VEGF antagonist fusion proteins

    Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10400025

    VEGF antagonist formulations suitable for intravitreal administration

    Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10400036

    Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or activin A

    Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10390522

    Non-human animals having a humanized programmed cell death 1 gene

    Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10392439

    Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R inhibitor

    Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10392432

    Human antibodies to influenza hemagglutinin

    Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10392430

    Methods of making nucleic acid molecules encoding modified chimeric polypeptides with improved pharmacokinetic properties

    Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10377817

    Human antibodies to GREM1

    Expires Mon Aug 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10370449

    Methods for treating skin infection by administering an IL-4R antagonist

    Expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10358495

    Anti-LAG3 antibodies and uses thereof

    Expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10358487

    Anti-ANGPTL3 antibodies and uses thereof

    Expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10342876

    Process for reducing subvisible particles in a pharmaceutical formulation

    Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10314904

    Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist

    Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10316105

    Anti-TIE2 antibodies and uses thereof

    Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10306874

    Non-human animals having a humanized lymphocyte-activation gene 3

    Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10285388

    Non-human animals having a disruption in a C9ORF72 locus

    Expires Mon May 09 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10278374

    Genetically modified mice and engraftment

    Expires Mon May 02 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10266588

    Method of treating osteoarthritis with an antibody to NGF

    Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10266582

    GPR156 variants and uses thereof

    Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10261094

    Competitive ligand binding assay for detecting neutralizing antibodies

    Expires Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10259870

    Anti-ANGPTL8 antibodies and uses thereof

    Expires Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10251938

    Angiopoietin-based interventions for treating cerebral malaria

    Expires Mon Apr 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10253102

    Antigen-binding proteins that activate the leptin receptor

    Expires Mon Apr 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10246509

    Restricted immunoglobulin heavy chain mice

    Expires Mon Mar 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10233250

    Human antibodies to the glucagon receptor and methods of use thereof for lowering blood glucose or ketone levels

    Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10212923

    Humanized dipeptidyl-peptidase IV (DPP4) animals

    Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10206379

    Non-human animals having a humanized signal-regulatory protein gene

    Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10196613

    Stem cells for modeling type 2 diabetes

    Expires Mon Jan 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10189901

    Methods for improving cardiac function by administering an antibody that activates APLNR

    Expires Mon Jan 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10179819

    Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof

    Expires Mon Jan 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10162933

    High resolution allele identification

    Expires Mon Dec 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10155811

    APLNR modulators and uses thereof

    Expires Mon Dec 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10137193

    Methods for treating or preventing asthma by administering an IL-4R antagonist

    Expires Mon Nov 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10130681

    Use of a VEGF antagonist to treat angiogenic eye disorders

    Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10123518

    Genetically modified non-human animals and methods of use thereof

    Expires Mon Nov 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10125188

    Human antibodies to respiratory syncytial virus F protein and methods of use thereof

    Expires Mon Nov 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10111953

    Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)

    Expires Mon Oct 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron UK have?

837 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron UK patents expire?

26 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources Β· Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.